Even though not undisputed, the presence of specific additional molecular and genetic lesions, in particular, the kinase activating FLT3 internal tandem duplication (ITD) may modulate the response of APL patients to atRA-based therapy [47,70]. This evidence concerns the gene FLT3 and acute promyelocytic leukemia.